Abstract
Complete surgical resection may be a curative treatment option for a fraction of patients with oligometastatic colorectal cancer. Use of adjuvant chemotherapy for patients with colorectal cancer is administered with the intention to eradicate microscopic foci of remaining disease which may be present and otherwise clinically undetectable after surgery in order to improve survival outcomes further. Historically, clinical trials evaluating use of systemic treatment options like cytotoxic chemotherapy or monoclonal antibodies have been hampered by slower-than-anticipated patient accrual. Nonetheless, available data have suggested that there is some improvement in survival outcomes with fluoropyrimidine-based chemotherapy. This chapter covers previous adjuvant trials for patients with resected liver-limited metastatic colorectal cancer. Evolving technologies with circulating tumor DNA may identify with high sensitivity the presence of minimal residual disease for whom future intervention trials in the adjuvant setting may best focus on patients in this setting with an especially high risk of recurrence.
| Original language | English (US) |
|---|---|
| Title of host publication | Colorectal Liver Metastasis |
| Publisher | Springer International Publishing |
| Pages | 301-308 |
| Number of pages | 8 |
| ISBN (Electronic) | 9783031093234 |
| ISBN (Print) | 9783031093227 |
| DOIs | |
| State | Published - Jan 1 2022 |
| Externally published | Yes |
Keywords
- Adjuvant chemotherapy
- Circulating tumor DNA
- Clinical trials
- Colorectal cancer
- Liver metastasis
ASJC Scopus subject areas
- General Medicine